William Grossman
CIK 1730229 · Interim Chief Medical Officer · last filed 2026-09-24
William Grossman is an Interim Chief Medical Officer who has filed 22 SEC Form 4 insider transactions across 5 companies since 2018. The most recent filing shows the insider bought $10.1K of ENGN on Sep 24, 2026. Across all open-market trades the lifetime net is −$422.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $447.5K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RCUS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
2130 W. HOLCOMBE BLVD., STE. 800
HOUSTON, TX 77030
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ENGN | Interim Chief Medical Officer | 5,102 | $1.58 | $8.1K | $10.1K | 1 | 2026-09-24 |
| ENGNW | Interim Chief Medical Officer | — | $0.23 | — | $0 | 2 | 2026-06-17 |
| Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Director | — | $21.53 | — | $0 | 5 | 2026-04-23 |
| RCUS | Chief Medical Officer | 24,741 | $17.76 | $439.4K | -$432.2K | 11 | 2021-06-21 |
| BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | Sr. VP, Chief Medical Officer | 2,687 | $0.07 | $201 | $0 | 3 | 2019-02-07 |
Recent Filings
22 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-24 | ENGN | Buy (P) | +5,102 | $10.1K | EDGAR |
| 2026-06-17 | ENGNW | Grant (A) | — | $0 | EDGAR |
| 2026-04-23 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Disp (D) | — | $0 | EDGAR |
| 2025-11-07 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | — | $0 | EDGAR |
| 2025-07-10 | ENGNW | Grant (A) | — | $0 | EDGAR |
| 2025-06-04 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-05-28 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-19 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-21 | RCUS | Sell (S) | −7,065 | -$168.8K | EDGAR |
| 2021-04-26 | RCUS | Sell (S) | −4,133 | -$129.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.